- Home
- ONIT vs IVA Comparison
ONIT vs IVA Comparison
Compare ONIT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONIT
- IVA
- Stock Information
- Founded
- ONIT 1988
- IVA 2011
- Country
- ONIT United States
- IVA France
- Employees
- ONIT 4200
- IVA N/A
- Industry
- ONIT
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- ONIT
- IVA Health Care
- Exchange
- ONIT NYSE
- IVA Nasdaq
- Market Cap
- ONIT 305.7M
- IVA 359.6M
- IPO Year
- ONIT 1996
- IVA 2020
- Fundamental
- Price
- ONIT $38.67
- IVA $3.01
- Analyst Decision
- ONIT Strong Buy
- IVA Strong Buy
- Analyst Count
- ONIT 2
- IVA 4
- Target Price
- ONIT $52.50
- IVA $10.50
- AVG Volume (30 Days)
- ONIT 38.7K
- IVA 18.3K
- Earning Date
- ONIT 07-31-2025
- IVA 03-26-2025
- Dividend Yield
- ONIT N/A
- IVA N/A
- EPS Growth
- ONIT 248.50
- IVA N/A
- EPS
- ONIT 2.98
- IVA N/A
- Revenue
- ONIT $986,700,000.00
- IVA $14,591,573.00
- Revenue This Year
- ONIT $7.68
- IVA $15.38
- Revenue Next Year
- ONIT $9.23
- IVA $24.22
- P/E Ratio
- ONIT $12.97
- IVA N/A
- Revenue Growth
- ONIT N/A
- IVA N/A
- 52 Week Low
- ONIT $22.40
- IVA $1.53
- 52 Week High
- ONIT $41.27
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- ONIT 58.69
- IVA 40.84
- Support Level
- ONIT $37.20
- IVA $3.00
- Resistance Level
- ONIT $37.99
- IVA $3.23
- Average True Range (ATR)
- ONIT 1.22
- IVA 0.21
- MACD
- ONIT 0.06
- IVA -0.04
- Stochastic Oscillator
- ONIT 84.26
- IVA 5.08
About ONIT ONITY GROUP INC
Onity Group Inc is a non-bank mortgage servicer and originator providing solutions through its brands, PHH Mortgage and Liberty Reverse Mortgage. PHH Mortgage is one of the servicers in the country, focused on delivering a variety of servicing and lending programs. Liberty is one of the nation's reverse mortgage lenders dedicated to education and providing loans that help customers meet their personal and financial needs.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.